Literature DB >> 18419885

Tuberculosis in a low-incidence US area: local consequences of global disruptions.

M N Lobato1, M H Mohamed, J L Hadler.   

Abstract

SETTING: Tuberculosis (TB) in the United States is increasingly concentrated among foreign-born persons. The northeastern states, including Connecticut, are among those with the highest proportion of foreign-born patients.
METHODS: This retrospective analysis of surveillance data from Connecticut for 1996 through 2005 compared TB case rates and risk factors among US-born and foreign-born persons.
RESULTS: Between 1996 and 2005, TB cases declined by 8.7% in foreign-born persons and by 53.6% in US-born persons. The median annual incidence rate for foreign-born persons was 19.7 cases per 100000 population compared with 1.5 for US-born persons. Refugees had the highest TB rate (116 cases/100000) in the first year of their arrival. Resistance to any drug was more common among foreign-born persons (15.0%) than among US-born persons (9.3%). Although the proportion of multidrug-resistant TB was highest among foreign-born persons with prior TB (5.6%), most cases occurred in those without prior TB. Risk factors for TB, such as human immunodeficiency virus infection, drug use, incarceration and homelessness, were more common among US-born TB patients than among foreign-born patients.
CONCLUSIONS: Although TB case rates for US-born persons in Connecticut have declined dramatically, foreign-born persons, including refugees fleeing conflict, contribute disproportionately to the TB burden. Future efforts to eliminate TB must be directed toward immigrants and refugees.

Entities:  

Mesh:

Year:  2008        PMID: 18419885

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model.

Authors:  Jamie P Morano; Alexei Zelenev; Mary R Walton; R Douglas Bruce; Frederick L Altice
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

2.  Spatial clusters of latent tuberculous infection, Connecticut, 2010-2014.

Authors:  J Mullins; M N Lobato; K Bemis; L Sosa
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

3.  Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals.

Authors:  Nathan W Furukawa; Mahri Z Haider; Sheanne J Allen; Sherry L Carlson; Scott W Lindquist
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

4.  Civil Surgeon Tuberculosis Evaluations for Foreign-Born Persons Seeking Permanent U.S. Residence.

Authors:  Kelley Bemis; Andrew Thornton; Alfonso Rodriguez-Lainz; Phil Lowenthal; Miguel Escobedo; Lynn E Sosa; Andrew Tibbs; Sharon Sharnprapai; Kathleen S Moser; Jennifer Cochran; Mark N Lobato
Journal:  J Immigr Minor Health       Date:  2016-04

5.  Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012.

Authors:  Rachel J Bennett; Stephanie Brodine; Jill Waalen; Kathleen Moser; Timothy C Rodwell
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

6.  Migrants and emerging public health issues in a globalized world: threats, risks and challenges, an evidence-based framework.

Authors:  Bd Gushulak; J Weekers; Dw Macpherson
Journal:  Emerg Health Threats J       Date:  2010-03-31

7.  Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits.

Authors:  Jason M Lempp; Margan J Zajdowicz; Arlene L Hankinson; Sean R Toney; Lisa W Keep; James D Mancuso; Gerald H Mazurek
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

8.  Collaboration between municipal and specialist public health care in tuberculosis screening in Norway.

Authors:  Ingunn Harstad; Anne H Henriksen; Eli Sagvik
Journal:  BMC Health Serv Res       Date:  2014-05-27       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.